Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.81 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.81 |
| ▸ | JAK3 | P52333 | 5/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.67 |
| ▸ | FLT3 | P36888 | 4/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | FLT4 | P35916 | 2/20 | 0.65 |
| ▸ | KDR | P35968 | 5/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.65 |
| ▸ | RET | P07949 | 3/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.65 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | CSF1R | P07333 | 2/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.65 |
| ▸ | FLT1 | P17948 | 2/20 | 0.65 |
| ▸ | LTK | P29376 | 2/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144620 | 1.00 | PDPK1 (0.81) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL20944 | 0.90 | TLK2 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL20945 | 0.90 | TLK2 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL5728570 | 0.83 | PDPK1 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL5728571 | 0.83 | PDPK1 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL394103 | 0.81 | NTRK1 (0.85) | TLK2JAK3PDGFRBFLT3KIT | |
| SCHEMBL10091844 | 0.81 | NTRK1 (0.85) | TLK2JAK3PDGFRBFLT3KIT | |
| SCHEMBL5728440 | 0.81 | PDPK1 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL5728434 | 0.81 | PDPK1 (1.00) | PDPK1TLK2JAK3PDGFRBFLT3 | |
| SCHEMBL397847 | 0.80 | NTRK1 (0.89) | TLK2JAK3PDGFRBFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | claimed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | PDPK1 4/4885TLK2 847/4885JAK3 2537/4885 |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | PDPK1 370/4885TLK2 181/4885JAK3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.